FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980408069> ?p ?o ?g. }

• W2980408069 abstract "Abstract Abstract 855 Previously, we demonstrated that changing residue Leu17 (BPTI/Aprotinin numbering) to Arg in Kunitz domain 1 (73-residue KD1-L17R) of TFPI-2 abolishes its anticoagulant functions and enhances its plasmin inhibition (Bajaj et al., J Biol Chem 286, 4329–4340, 2011). In that study we used the entire KD1 domain, which in addition to the core structural homologous region of BPTI (58 residues) included 9 residues on the N-terminal and 6 residues on the C-terminal side of the protein. Conformation of these 15 residues may be different in the isolated KD1-domain as compared to the complete TFPI-2 molecule. Thus, these residues could be potentially immunogenic. To address these concerns, we investigated weather N- and C-terminal regions of 73-residue KD1-L17R could be cleaved upon prolonged incubation with thrombin (IIa). Incubation of 73-residue KD1-L17R with IIa for 72 hrs yielded smaller version(s) of KD1-L17R as analyzed by SDS-PAGE. N-terminal sequence and MALDI-TOF/ESI mass spectrometry analyses revealed three closely related species present in the truncated KD1-L17R preparations (Fig. 1). Species 1 has Gly-Asn-Asn as the amino terminus and Val-Pro-Lys as the C-terminus. Species 2 and 3 are similar to species 1 except species 2 is produced after losing Gly and Asn from the N-terminus, whereas species 3 is produced after losing Val-Pro-Lys from the C-terminus. Thus, all three species have the intact core Kunitz domain with minor variations at the N- and C-terminus regions. Further, these species are cleaved at the viable albeit very slow IIa-cleavage sites; herein, these species are collectively referred to as truncated KD1-L17R. A plausible mechanism for proteolysis at these cleavage sites is shown in Fig. 2. Similar to the 73-residue KD1-L17R, the truncated preparations did not inhibit (Ki > 3 μM) plasma kallikrein, factor (F) XIa, FVIIa/soluble tissue factor, FXa, activated protein C, tissue plasminogen activator (tPA), IIa and IIa/soluble thrombomodulin. Importantly, the truncated KD1-L17R preparations inhibited plasmin with Ki ∼1.2 nM. Further, the truncated KD1-L17R inhibited tPA-induced plasma clot fibrinolysis with an apparent IC50 of ∼0.37 μM, a value similar to that obtained with the 73-residue KD1-L17R and BPTI. Two lysine analogues, Epsilon amino caproic acid (EACA) and tranexamic acid (TE) inhibited tPA-induced plasma clot fibrinolysis with an apparent IC50 of ∼80 μM and ∼20 μM, respectively. Further, efficacy of truncated KD1-L17R was tested in a mouse liver laceration model of bleeding. As compared to saline, the amount of blood loss was reduced by ∼65% by truncated KD1-L17R (N=6, p 0.001), ∼70% by BPTI (N=10, p 0.003), ∼52% by TE (N=10, p 0.019) and ∼25% by EACA (N=16, p 0.03). We also observed seizures in four (25%) of the animals treated with a single dose of EACA. In conclusion, truncated KD1-L17R is an effective antifibrinolytic agent similar to the 73-residue KD1-L17R and BPTI/Aprotinin. Although lysine analogues are relatively effective in reducing blood loss, EACA caused seizures in our studies. These observations are consistent with recent reports that one of the major side effects of lysine analogues is seizures (Martin et al., J Cardiothorac Vasc Anesth 25, 20–25, 2011; Koster and Schirmer, Curr Opin Anaesthesiol 24, 92–97, 2011). We conclude that truncated KD1-L17R may serve as an excellent alternative to BPTI and lysine analogues in preventing blood loss during major surgeries including coronary artery bypass graft (CABG) surgery. We are currently expressing the 60-residue KD1-L17R (NH2Asn-Ala-Glu······Ile-Glu-Lys) protein for further efficacy studies. We are also generating additional mutant(s) on the 60-residue KD1-L17R molecule for achieving increased plasmin potency without provoking anticoagulant functions. Supported By HL89661 and HL36365. Disclosures: No relevant conflicts of interest to declare." @default.
• W2980408069 created "2019-10-25" @default.
• W2980408069 creator A5000263788 @default.
• W2980408069 creator A5003299197 @default.
• W2980408069 creator A5022896212 @default.
• W2980408069 creator A5037369625 @default.
• W2980408069 creator A5059846507 @default.
• W2980408069 creator A5064068211 @default.
• W2980408069 creator A5071883004 @default.
• W2980408069 creator A5049007284 @default.
• W2980408069 date "2011-11-18" @default.
• W2980408069 modified "2023-09-29" @default.
• W2980408069 title "Antifibrinolytic Efficacy of Truncated L17R Mutant of Kunitz Domain 1 (KD1) of Tissue Factor Pathway Inhibitor-2 (TFPI-2): Comparison with Lysine Analogues" @default.
• W2980408069 doi "https://doi.org/10.1182/blood.v118.21.855.855" @default.
• W2980408069 hasPublicationYear "2011" @default.
• W2980408069 type Work @default.
• W2980408069 sameAs 2980408069 @default.
• W2980408069 citedByCount "0" @default.
• W2980408069 crossrefType "journal-article" @default.
• W2980408069 hasAuthorship W2980408069A5000263788 @default.
• W2980408069 hasAuthorship W2980408069A5003299197 @default.
• W2980408069 hasAuthorship W2980408069A5022896212 @default.
• W2980408069 hasAuthorship W2980408069A5037369625 @default.
• W2980408069 hasAuthorship W2980408069A5049007284 @default.
• W2980408069 hasAuthorship W2980408069A5059846507 @default.
• W2980408069 hasAuthorship W2980408069A5064068211 @default.
• W2980408069 hasAuthorship W2980408069A5071883004 @default.
• W2980408069 hasConcept C104317684 @default.
• W2980408069 hasConcept C141071460 @default.
• W2980408069 hasConcept C143065580 @default.
• W2980408069 hasConcept C185592680 @default.
• W2980408069 hasConcept C2775895851 @default.
• W2980408069 hasConcept C2776016237 @default.
• W2980408069 hasConcept C2780799893 @default.
• W2980408069 hasConcept C2781338088 @default.
• W2980408069 hasConcept C515207424 @default.
• W2980408069 hasConcept C55493867 @default.
• W2980408069 hasConcept C71240020 @default.
• W2980408069 hasConcept C71924100 @default.
• W2980408069 hasConceptScore W2980408069C104317684 @default.
• W2980408069 hasConceptScore W2980408069C141071460 @default.
• W2980408069 hasConceptScore W2980408069C143065580 @default.
• W2980408069 hasConceptScore W2980408069C185592680 @default.
• W2980408069 hasConceptScore W2980408069C2775895851 @default.
• W2980408069 hasConceptScore W2980408069C2776016237 @default.
• W2980408069 hasConceptScore W2980408069C2780799893 @default.
• W2980408069 hasConceptScore W2980408069C2781338088 @default.
• W2980408069 hasConceptScore W2980408069C515207424 @default.
• W2980408069 hasConceptScore W2980408069C55493867 @default.
• W2980408069 hasConceptScore W2980408069C71240020 @default.
• W2980408069 hasConceptScore W2980408069C71924100 @default.
• W2980408069 hasLocation W29804080691 @default.
• W2980408069 hasOpenAccess W2980408069 @default.
• W2980408069 hasPrimaryLocation W29804080691 @default.
• W2980408069 hasRelatedWork W1503593492 @default.
• W2980408069 hasRelatedWork W1513635327 @default.
• W2980408069 hasRelatedWork W1517676588 @default.
• W2980408069 hasRelatedWork W1967322305 @default.
• W2980408069 hasRelatedWork W1967646775 @default.
• W2980408069 hasRelatedWork W1978275166 @default.
• W2980408069 hasRelatedWork W1990004106 @default.
• W2980408069 hasRelatedWork W2028423657 @default.
• W2980408069 hasRelatedWork W2040465501 @default.
• W2980408069 hasRelatedWork W2047083068 @default.
• W2980408069 hasRelatedWork W2059365572 @default.
• W2980408069 hasRelatedWork W2061009315 @default.
• W2980408069 hasRelatedWork W2070040967 @default.
• W2980408069 hasRelatedWork W2096088466 @default.
• W2980408069 hasRelatedWork W2552708678 @default.
• W2980408069 hasRelatedWork W2553759941 @default.
• W2980408069 hasRelatedWork W2575949642 @default.
• W2980408069 hasRelatedWork W3101005196 @default.
• W2980408069 hasRelatedWork W3146693449 @default.
• W2980408069 hasRelatedWork W3153269046 @default.
• W2980408069 isParatext "false" @default.
• W2980408069 isRetracted "false" @default.
• W2980408069 magId "2980408069" @default.
• W2980408069 workType "article" @default.